Current therapeutic procedures in Dravet syndrome
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Dravet syndrome is a highly pharmaco‐resistant form of epilepsy. Valproate and benzodiazepines are the first‐line treatment but are usually insufficient therapeutic options. Lamotrigine, carbamazepine and high doses of intravenous phenobarbital can aggravate seizures and should be avoided. Topiramate, levetiracetam, bromide and ketogenic diet also provide substantial efficacy as adjunctive therapy and procedures. Stiripentol is the only new drug to demonstrate efficacy when combined with valproate and clobazam, as shown in two independent double‐blind controlled trials dedicated to Dravet children. In order to avoid side effects (mainly loss of appetite and loss of weight) resulting from the inhibition of cytochromes P450 by stiripentol, the prescribed doses of valproate and clobazam should be reduced. Stiripentol has a proper antiepileptic effect and enhances GABAergic neurotransmission by acting on the alpha‐3 subunit of GABA A receptors. Stiripentol was approved as an orphan drug in Europe in 2007 for adjunctive therapy in Dravet syndrome. More than 500 Dravet patients have currently been satisfactorily treated and recent experiments in Japan have confirmed stiripentol’s benefit. In practice, valproate should be initiated at the first onset of complicated febrile seizure in Dravet patients. Relapses justify the addition of clobazam and stiripentol when available. Topiramate and a ketogenic diet are alternatives in pharmaco‐resistant cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yu, F. H., Mantegazza, M., Westenbroek, R. E., Robbins, C. A., Kalume, F., Burton, K. A., Spain, W. J., McKnight, G. S., Scheuer, T., & Catterall, W. A. (2006) · Nature Neuroscience · doi:10.1038/nn1754 · Cited by 1,173
Chiron, C., Marchand, M., Tran, A., Rey, E., d'Athis, P., Vincent, J., Dulac, O., & Pons, G. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03157-3 · Cited by 568 · cited 3×
“Most adverse events are related to a significant increase in the plasma concentration of VPA, CLB and Nor-CLB after the addition of STP; these effects disappear when the dose of comedication is decreased.(9,10) They include drowsiness, ataxia, nausea, abdominal pain, and loss of appetite resulting in weight loss.”
BackgroundMethodSelf-citationLamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy
Guerrini, R., Dravet, C., Genton, P., Belmonte, A., Kaminska, A., & Dulac†, O. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01413.x · Cited by 467 · cited 1×
“This effect was observec with Lamotrigine in 80% of 20 patients recruited in three epilepsy centers.(3) A>50% increase in generalized tonic-clonic seizures (GTCS) was observed in 40% of 20 patients, and an increase in myoclonic seizures in 33% of 18 patients.”
BackgroundStiripentol: Efficacy and Tolerability in Children with Epilepsy
Perez, J., Chiron, C., Musial, C., Rey, E., Blehaut, H., D'Athis, P., Vincent, J., & Dulac, O. (1999) · Epilepsia · doi:10.1111/j.1528-1157.1999.tb02048.x · Cited by 148
Self-citation
Cited by
The phenotypic spectrum of SCN8A encephalopathy
Larsen, J., Carvill, G. L., Gardella, E., Kluger, G., Schmiedel, G., Barisic, N., Depienne, C., Brilstra, E., Mang, Y., Nielsen, J. E. K., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001211 · Cited by 285
Miller, I., Scheffer, I. E., Gunning, B., Sanchez-Carpintero, R., Gil-Nagel, A., Perry, M. S., Saneto, R. P., Checketts, D., Dunayevich, E., Knappertz, V., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0073 · Cited by 267
Tau reduction prevents disease in a mouse model of Dravet syndrome
Gheyara, A. L., Ponnusamy, R., Djukic, B., Craft, R. J., Ho, K., Guo, W., Finucane, M. M., Sanchez, P. E., & Mucke, L. (2014) · Annals of Neurology · doi:10.1002/ana.24230 · Cited by 138
“Dravet syndrome is among the most drug-resistant forms of epilepsy.(22,23) Drugs currently used as first-line therapy for Dravet syndrome, valproate and benzodiazepines, have limited efficacy, and other antiepileptic drugs, including lamotrigine, vigabatrin, and carbamazepine, even exacerbate symptoms in Dravet patien…”
Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening
Griffin, A., Hamling, K. R., Hong, S., Anvar, M., Lee, L. P., & Baraban, S. C. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00573 · Cited by 103
“…Nob Gabapentin Noa Noh Rufinamide Noa Nof,g No. of AEDs predictive 14/14 1/4 2/3 5/9 4/7 1/3 a (Villas et al., 2017), b(Hawkins et al., 2017), c(Chiron, 2011); d (Baraban et al., 2013); eHong et al. (2016), f see Figure 3, g (Griffin et al., 2017), h (Dinday and Baraban, 2015), i (Eimon et…”
Background
Metadata
- Authors
- CHIRON, C.
- Venue
- Developmental Medicine & Child Neurology
- Publisher
- Wiley
- Published
- 2011-04
- Volume
- 53
- Issue
- s2
- Pages
- 16-18
- ISSN
- 0012-1622 (ISSN-L)
- 1469-8749
- OpenAlex
- W2166619593
- Cited by
- 55
- References
- 4
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current therapeutic procedures in Dravet syndrome. https://app.cochat.ai/papers/10.1111/j.1469-8749.2011.03967.x
- The paper
- CHIRON, C. (2011). Current therapeutic procedures in Dravet syndrome. Developmental Medicine & Child Neurology. https://doi.org/10.1111/j.1469-8749.2011.03967.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.